Cardiovascular

Bioabsorbable Everolimus-Eluting Stent: 6-Month Angiographic and IVUS Results

March 26, 2007
Patrick Serruys
Patrick Serruys

Spencer King
Spencer King

PATRICK SERRUYS, Erasmus University, Rotterdam
COMMENT: SPENCER KING, Piedmont Hospital, Atlanta

REFERENCE: Abstract 2402-3, American College of Cardiology New Orleans
Six-months follow-up of patients receiving a new bioabsorbable drug-eluting stent are favourable, according to Patrick Serruys whose group has been investigating the stent which elutes everolimus in a group of 30 patients. During the ACC Annual Meeting in New Orleans he discussed with Peter Goodwin the potential benefits the new device can bring to coronary patients.

Add podcast to iTunes

Similar Interviews

  • Audio Journal of Cardiovascular Medicine: Sirolimus-Eluting Better Than Uncoated Stents for Primary Angioplasty

    • CHRISTIAN SPAULDING, Cochin Hospital, Paris REFERENCE: N Engl J Med 2006;355:1093, 1105,1169 Two leading articles in the same edition of the New

  • Primary Angioplasty: Sirolimus Eluting Stent Cuts MACE Rates In Half

    • Christian Spaulding, Rene Descartes University American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta Primary PCI is even more effective

  • TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?

    • Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida

    1. [...] Patrick Serruys. Spencer King. PATRICK SERRUYS, Erasmus University, Rotterdam COMMENT: SPENCER KING, Piedmont Hospital, Atlanta. REFERENCE: Abstract 2402-3, American College of Cardiology New Orleans Six-months follow-up of patients … …more [...]

      Posted by cardiovascular-medicine » Blog Archive » braunwalds heart disease a textbook of cardiovascular medicine | August 12, 2007, 8:11 pm

    Post a comment